This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB05630/identifier/chebi/
n14http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05630/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/drug/DB05630/identifier/pharmgkb/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB05630/identifier/kegg-drug/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB05630/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05630
rdf:type
n3:Drug
n3:description
Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials. Sodium stibogluconate is sold in the UK as Pentostam (manufactured by GlaxoSmithKline). Widespread resistance has limited the utility of sodium stibogluconate, and in many parts of the world, amphotericin or miltefosine are used instead. It is also being investigated as an anti-tumor agent.
n3:generalReferences
# Murray HW, Berman JD, Davies CR, Saravia NG: Advances in leishmaniasis. Lancet. 2005 Oct 29-Nov 4;366(9496):1561-77. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16257344
n3:group
investigational approved
n3:indication
For the treatment of various types of a protozoal infection called leishmaniasis, which may result from sandfly bites in tropical and temperate parts of the world. Also investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
owl:sameAs
n12:DB05630 n18:DB05630
dcterms:title
Sodium stibogluconate
adms:identifier
n5:PA164743129 n7:Sodium_stibogluconate n15:D00582 n16:28148 n17:DB05630
n3:mechanismOfAction
Sodium stibogluconate directly inhibits DNA topoisomerase I leading to inhibition of both DNA replication and transcription.
n3:synonym
Pentostam Myostibin Antimony sodium gluconate Natrii stibogluconas Stibanate Stibanose Stibogluconate de sodium Stibatin Antimony (v) derivative OF sodium gluconate Stibinol Trisodium 1-{[3-carboxylato-5-(1,2-dihydroxyethyl)-1-hydroxy-2,6,7-trioxa-1lambda(5)-stibabicyclo[2.2.1]hept-1-yl]oxy}-5-(1,2-dihydroxyethyl)-1-oxido-2,6,7-trioxa-1lambda(5)-stibabicyclo[2.2.1]heptane-3-carboxylate nonahydrate Estibogluconato sodico Sodium stibogluconate
n3:toxicity
The main symptoms of antimony overdosage are gastro-intestinal disturbances (nausea, vomiting and severe diarrhoea). Haemorrhagic nephritis and hepatitis may also occur.
n13:hasConcept
n14:M0001476
n3:IUPAC-Name
n6:271B45C3-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B45C9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B45C8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B45C5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B45C6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B45C7-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B45C2-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:P01CB02
n3:H-Bond-Acceptor-Count
n6:271B45CF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B45D0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B45CA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B45CB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B45CD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B45CC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B45CE-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals Protozoa
n3:casRegistryNumber
16037-91-5
n3:category
n3:Bioavailability
n6:271B45D5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B45D7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B45D8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B45D4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B45D3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B45D6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B45C4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B45D1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B45D2-363D-11E5-9242-09173F13E4C5